



## BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

August 21, 2018

RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer will present at the Rodman & Renshaw 20<sup>th</sup> Annual Global Investment Conference taking place at the St. Regis Hotel in New York, NY.

### Presentation details:

Date: Thursday – September 6, 2018  
Time: 4:15 PM Eastern Time

The presentation will be webcast live and can be accessed in the [investor section](#) (events page) of the BDSI website. For those who are not available to listen to the live broadcast, a replay of the webcast will be available.

### About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA<sup>®</sup>) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.

For more information, please visit or follow us:

Internet: [www.bdsi.com](http://www.bdsi.com)  
Facebook: [Facebook.com/BioDeliverySI](https://www.facebook.com/BioDeliverySI)  
Twitter: @BioDeliverySI

BUNAVAIL<sup>®</sup> (buprenorphine and naloxone) buccal film (CIII) and BELBUCA<sup>®</sup> (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit [www.bdsi.com](http://www.bdsi.com) where the Company promptly posts press releases, SEC filings, and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit [www.belbuca.com](http://www.belbuca.com) and for full prescribing and safety information on BUNAVAIL, please visit [www.bunavail.com](http://www.bunavail.com).

© 2018 BioDelivery Sciences International, Inc. All rights reserved.

### Contacts

Mary Coleman  
Vice President, Investor and Public Relations  
BioDelivery Sciences International, Inc.  
919-582-9050  
[mcoleman@bdsi.com](mailto:mcoleman@bdsi.com)

 [Primary Logo](#)

Source: BioDelivery Sciences International, Inc.